Drug intelligence / Profile preview

docosahexaenoic acid + eicosapentaenoic acid + gamma-linolenic acid

Development stage
Unknown
Lead developer
Nordic Naturals
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination supplement containing three polyunsaturated fatty acids: docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and gamma-linolenic acid (GLA). DHA and EPA are long-chain omega-3 fatty acids primarily found in fish oil, while GLA is an omega-6 fatty acid commonly derived from borage or evening primrose oil. This combination is designed to provide both anti-inflammatory and lipid-modifying effects. Mechanistically, these fatty acids modulate the production of eicosanoids such as prostaglandins and leukotrienes involved in inflammation. The combined supplementation has been shown to improve symptoms of dry eye disease by reducing inflammatory cytokines like TNF-alpha and IL-1β[2][5]. It also favorably alters blood lipid profiles by lowering triglycerides and LDL cholesterol[3], supports cardiovascular health[5], may benefit cognitive function[5], skin conditions such as eczema[5], metabolic syndrome, diabetes-related neuropathy, menopausal symptoms, arthritis/joint health[5], and overall eye health including tear production[7]. The product is available as a dietary supplement under various brand names.

Brand names
Complete OmegaVisionPro EPA/DHA/GLAEquazen
Other names
omega-3 and omega-6 fatty acids combinationomega3 and omega-6 fatty acids combinationomega 3 and omega-6 fatty acids combinationDHA + EPA + GLA combinationomega-3/omega-6 blend
02

Targets

IL1B (Interleukin-1 beta)COX15-LOX (Lysyl Oxidase)

Beyond the preview

Go deeper on docosahexaenoic acid + eicosapentaenoic acid + gamma-linolenic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on docosahexaenoic acid + eicosapentaenoic acid + gamma-linolenic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call